Cite
HARVARD Citation
Forero‐Torres, A. et al. (n.d.). Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer. Cancer medicine. pp. 925-932. [Online].